Panagora Asset Management’s ADMA Biologics ADMA Stock Holding History

Panagora Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-989	Closed	-$2K	–	1708
2021 Q2	$2K	Sell	989 -126	-11%	-$222	﹤0.01%	2617
2021 Q1	$2K	Hold	1,115	–	–	﹤0.01%	2699
2020 Q4	$2K	Buy	+1,115	New	+$2.34K	﹤0.01%	2601
2020 Q2	–	Sell	-53,790	Closed	-$155K	–	2556
2020 Q1	$155K	Buy	+53,790	New	+$186K	﹤0.01%	1541

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Panagora Asset Management's ADMA Position: Q3 2021 in Review

Panagora Asset Management sold out of ADMA Biologics (ADMA) in Q3 2021, closing a stake of 989 shares — an estimated $2K sold.

Panagora Asset Management first reported a position in ADMA in Q1 2020 and held it in 4 quarters. The position peaked at $155K in Q1 2020. 72 funds tracked by Wall St. Rank hold ADMA as of Q3 2021.

Panagora Asset Management reported no remaining ADMA Biologics position as of Q3 2021 after selling out during the quarter.
Panagora Asset Management sold 989 ADMA Biologics shares in Q3 2021, an estimated $2K.
Panagora Asset Management first reported a position in ADMA Biologics in Q1 2020 and held it in 4 quarters.
Panagora Asset Management's ADMA Biologics position peaked at $155K in Q1 2020.
72 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.